537STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
نویسندگان
چکیده
537. STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/ Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96 Catherine Creticos, MD; Cynthia Brinson,; Cheryl Mcdonald, MD; Sorana SegalMaurer, MD; Indira Brar, MD; BarbaraWade,; Will Garner, PhD; Danielle Porter,; Shampa De-Oertel, PhD; Amy Weinberg, NP; Toni Sparrow; Howard Brown Health Center, Chicago, IL; Central Texas Clinical Research, Austin, TX; Tarrant County Infection Disease Associates, Fort Worth, TX; Infectious Disease, New York Hospital Queens, Flushing, NY; Infectious Diseases, Henry Ford Hospital, Detroit, MI; Center for the Prevention and Treatment of Infections, Pensacola, FL; Gilead Sciences, Foster City, CA; Gilead Sciences, Fostser City, CA
منابع مشابه
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials
The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naïve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, ...
متن کاملSwitching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
BACKGROUND Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability of switching to this regimen compared with ...
متن کاملNew option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-naïve population. When compared with efavirenz-based therapy, improved tolerability with rilpivirine-based therap...
متن کاملSwitching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
BACKGROUND Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricit...
متن کاملTenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
BACKGROUND Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere. METHODS We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive eithe...
متن کامل